However, in SLE, a similar disease driven by type-1 IFNs, ncMs were shown to have inflammatory properties (through the release of cytokines) and antigen-presenting capabilities through expression of HLA-DR, CD80, and CD8634. This evidence concerns the gene CD80 and systemic lupus erythematosus.